Astellas unveils new Japan site for cell therapy research arm Universal Cells, transferring 12 roles overseas

Some six years after picking up Seattle’s Universal Cells for $102 million, Astellas Pharma is opening a second location for the subsidiary in its home country of Japan—and transferring a dozen roles along the way.